AbTherx and Rondo Therapeutics Announce Multi-Program Antibody Discovery Collaboration
-
End to US government shutdown in sight as Democrats quarrel
-
Trump threatens air traffic controllers over shutdown absences
-
US to remove warnings from menopause hormone therapy
-
UK water firm says 'highly likely' behind plastic pellet pollution incident
-
Syria's ex-jihadist president holds historic Trump talks
-
End to record-long US government shutdown in sight
-
France's ex-leader Sarkozy says after jail release 'truth will prevail'
-
Atalanta sack coach Juric after poor start to season
-
Trump threatens $1 billion action as BBC apologises for speech edit
-
Gattuso wants 'maximum commitment' as Italy's World Cup bid on the line
-
Indian capital car blast kills at least eight
-
Deadly measles surge sees Canada lose eradicated status
-
Brazil's Lula urges 'defeat' of climate deniers as COP30 opens
-
Strangled by jihadist blockade, Malians flee their desert town
-
US Supreme Court declines to hear case challenging same-sex marriage
-
'Fired-up' Fritz sees off Musetti in ATP Finals
-
Injured Courtois set to miss Belgium World Cup qualifiers
-
Bulatov, pillar of Russian contemporary art scene, dies at 92
-
Fritz sees off Musetti in ATP Finals
-
US strikes on alleged drug boats kill six more people
-
Sarkozy released from jail 'nightmare' pending appeal trial
-
COP30 has a mascot: the fiery-haired guardian of Brazil's forest
-
The Sudanese who told the world what happened in El-Fasher
-
Three things we learned from the Sao Paulo Grand Prix
-
ASC acquire majority share in Atletico Madrid
-
Ferrari boss tells Hamilton, Leclerc to drive, not talk
-
Bank of England seeks to 'build trust' in stablecoins
-
China suspends 'special port fees' on US vessels for one year
-
French court frees ex-president Sarkozy from jail pending appeal
-
No link between paracetamol and autism, major review finds
-
Typhoon Fung-wong floods Philippine towns, leaves 5 dead in its wake
-
France's Sarkozy says prison a 'nightmare' as prosecutors seek his release
-
Guinness maker Diageo picks new CEO after US tariffs cloud
-
China suspends 'special port fees' on US vessels
-
US senators take major step toward ending record shutdown
-
Typhoon Fung-wong leaves flooded Philippine towns in its wake
-
From Club Med to Beverly Hills: Assinie, the Ivorian Riviera
-
The 'ordinary' Arnie? Glen Powell reboots 'The Running Man'
-
Typhoon exposes centuries-old shipwreck off Vietnam port
-
French court to decide if ex-president Sarkozy can leave jail
-
China lifts sanctions on US units of South Korea ship giant Hanwha
-
Japan death row inmate's sister still fighting, even after release
-
Taylor sparks Colts to Berlin win as Pats streak hits seven
-
Dreyer, Pellegrino lift San Diego to 4-0 MLS Cup playoff win over Portland
-
Indonesia names late dictator Suharto a national hero
-
Fourth New Zealand-West Indies T20 washed out
-
Tanzania Maasai fear VW 'greenwashing' carbon credit scheme
-
Chinese businesswoman faces jail after huge UK crypto seizure
-
Markets boosted by hopes for deal to end US shutdown
-
Amazon poised to host toughest climate talks in years
NYSE - LSE
AbTherx and Rondo Therapeutics Announce Multi-Program Antibody Discovery Collaboration
Partnership leverages AbTherx’s Atlas™ Binary Fixed Light Chain Mouse to accelerate Rondo’s pipeline of bispecific antibodies
MOUNTAIN VIEW, CA / ACCESS Newswire / April 23, 2025 / AbTherx, Inc., a biotechnology company with innovative transgenic technologies that enable and accelerate antibody discovery, today announced a technology license agreement with Rondo Therapeutics. The partnership will leverage AbTherx's innovative Atlas Binary Fixed Light Chain Transgenic Mouse technology to deliver antibodies against targets selected by Rondo.
AbTherx's antibody discovery platform is powered by Atlas Mice, a suite of proprietary transgenic mouse technologies designed for unmatched performance and freedom-to-operate. This collaboration leverages AbTherx's novel, patent-pending Atlas Binary Fixed Light Chain Mouse, which enables native-like IgG bispecific antibodies that improve manufacturability and developability. This is accomplished by including two fixed light chain options, with optimized heavy-light chain pairing, that streamline bispecific antibody engineering and increase hit rates through an expanded antibody repertoire.
"We are excited to partner with the seasoned entrepreneurs and exceptional scientists at Rondo Therapeutics who have deep experience developing immune cell engaging bispecific antibodies," said Justin Mika, Chief Executive Officer of AbTherx. "AbTherx's antibody discovery technologies and capabilities complement Rondo's therapeutic expertise in immuno-oncology to provide an advantage that we believe will help bring new medicines to patients faster."
Under the terms of the agreement, Rondo has the right to develop and commercialize therapeutic antibodies resulting from the collaboration. AbTherx will receive research payments and is eligible to receive downstream clinical and commercial milestone payments, as well as royalties on net sales of products.
About Rondo Therapeutics
Rondo Therapeutics is a biopharmaceutical company exploring new frontiers in cancer therapy. Rondo is committed to advancing the field of immuno-oncology, with a focus on treating solid tumors that fail to respond to current therapies. Our solution is to create a new class of bispecific antibodies that safely engage the immune system to initiate and sustain a robust anti-tumor response and overcome the suppressive tumor microenvironment.
Learn more at: www.rondotx.com.
About AbTherx
AbTherx is advancing medicine with revolutionary technologies that accelerate and enable therapeutic antibody discovery. Through an exclusive license from Gilead Sciences, AbTherx has released Atlas™ Mice, a suite of novel transgenic technologies designed for unmatched performance and Freedom to Operate. For over 20 years, a core group of AbTherx's scientists have worked together to push the boundaries of antibody discovery technologies, resulting in more than 1,000 successful discovery campaigns and the development of 13 marketed therapeutics. AbTherx's industry-leading team creates transformative solutions to overcome the most demanding challenges in delivering innovative medicines. Committed to making its technologies accessible to all, AbTherx offers flexible partnering models that meet the needs of drug developers of all sizes. For more information, please visit www.abtherx.com.
Media Contact
Stacey Borders
[email protected]
SOURCE: AbTherx, Inc
View the original press release on ACCESS Newswire
Y.Nakamura--AMWN
